SKIN — The Beauty Health Company

Summary of SKIN (The Beauty Health Company) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $82.4 million, down 1.3% year-over-year, but an improvement from a double-digit decline in Q3.
• Consumables Revenue: Increased to $57.7 million, up 1.7% year-over-year, showcasing resilience in the recurring revenue model.
• Device Revenue: $24.7 million, a decline of 7.9% year-over-year, though an improvement from Q3 performance.
• Adjusted Gross Margin: Expanded to 67.4%, GAAP gross margin at 64.4%, driven by a favorable shift towards consumables.
• Adjusted EBITDA: Increased to $15 million in Q4, compared to $9 million in the prior year, with full-year adjusted EBITDA reaching $45.1 million, up from $12.3 million in 2024.
• Cash Position: Ended 2025 with approximately $232.7 million in cash, down 37% from 2024 due to debt restructuring efforts.

2. Strategic Updates and Business Highlights

• Market Position: The company is focusing on transitioning from a device placement model to a utilization model, aiming to enhance the productivity of its installed base of over 36,000 systems.
• Sales and Marketing Strategy: Emphasizing a value-based selling model, improving provider education, and refining marketing strategies to drive demand.
• Innovation Focus: Plans for disciplined product launches, including a next-generation HydraFacial system expected in 2028, and targeted development of clinically backed boosters.
• Consumer Trends: Noted increased engagement from diverse demographics, including men and Gen Z, with a shift towards outcome-driven treatment protocols.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $285 million and $305 million, reflecting a modest decline compared to 2025, with a more back-half weighted revenue cadence.
• Adjusted EBITDA Guidance: Projected between $35 million and $45 million for 2026.
• Q1 2026 Expectations: Revenue forecast of $63 million to $68 million, with anticipated challenges due to seasonal dynamics and macroeconomic pressures.

4. Bad News, Challenges, or Points of Concern

• Declining Device Revenue: Continued pressure in the capital equipment segment, with device sales expected to remain soft due to macroeconomic conditions.
• Churn Rate: Slightly higher churn rate in 2025, though improved in Q4; primarily affecting smaller accounts without dedicated support.
• Market Pressures: Ongoing challenges in the APAC region, particularly China, impacting overall performance and growth expectations.
• Competitive Landscape: Increased competition leading to longer sales cycles and pressures on pricing strategies.

5. Notable Q&A Insights

• Churn Management: The company is restructuring its sales and customer service teams to better support smaller accounts and reduce churn.
• Consumer Spending Trends: Consumers are becoming more selective, focusing on clinically proven results at accessible price points, which aligns with HydraFacial’s offerings.
• Sales Execution: The company is focused on improving sales execution and operational efficiencies to drive growth, particularly in the second half of 2026.
• Booster Strategy: The introduction of new boosters has been successful, with plans to continue launching clinically differentiated products to enhance provider engagement and consumer demand.

Overall, The Beauty Health Company is positioned for stabilization and gradual improvement in 2026, with a focus on operational execution and innovation to return to growth in 2027.